|Dr. Jay R. Luly||Pres, CEO & Director||998.3k||N/A||1956|
|Mr. Paul J. Mellett Jr.||Sr. VP of Fin. & Admin. and CFO||581.29k||657.31k||1955|
|Dr. Yat Sun Or||Sr. VP of R&D and Chief Scientific Officer||636.02k||1.99M||1952|
|Mr. Nathaniel S. Gardiner J.D.||Sr. VP, Gen. Counsel & Sec.||588.49k||715.69k||1954|
|Dr. Nathalie Adda||Sr. VP & Chief Medical Officer||620.01k||N/A||1966|
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Enanta Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 4.